PNC Financial Services Group
DMAC icon

PNC Financial Services Group’s DiaMedica Therapeutics DMAC Stock Holding History

PNC Financial Services Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99 Sell
14
-5
-26% -$31 ﹤0.01% 5148
2026
Q1 		$129 Sell
19
-38
-67% -$301 ﹤0.01% 5081
2025
Q4 		$454 Sell
57
-393
-87% -$2.94K ﹤0.01% 4860
2025
Q3 		$3.09K Buy
+450
New +$2.44K ﹤0.01% 4379

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PNC Financial Services Group's DMAC Position: Q2 2026 in Review

PNC Financial Services Group reduced its DiaMedica Therapeutics (DMAC) stake by 26% in Q2 2026, selling an estimated $31 and leaving 14 shares worth $99. The position accounts for ﹤0.01% of the portfolio, ranked #5148.

PNC Financial Services Group first reported a position in DMAC in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.09K in Q3 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • PNC Financial Services Group held 14 shares of DiaMedica Therapeutics worth $99 as of Q2 2026.
  • PNC Financial Services Group sold 5 DiaMedica Therapeutics shares in Q2 2026, an estimated $31.
  • DiaMedica Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5148 holding.
  • PNC Financial Services Group first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's DiaMedica Therapeutics position peaked at $3.09K in Q3 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.